PIPELINE DISCOVERY DEVELOPMENT MANUFACTURING

PIPELINE

Antengene's pipeline includes five clinical stage products, from phase2/3 and NDA stage ATG-010 for relapsed/refractory multiple myeloma, lymphomas and solid tumors; to ATG-008 that is in multi-regional clinical trial currently enrolling late stage HCC patients in Taiwan, S. Korea and mainland China. Two other phase 1 and phase 2 clinical stage drugs, ATG-016 and ATG-019, are being studied in multiple cancer types, including MDS, colorectal and prostate cancers. ATG-527, studied in a completed phase 1 trial, is being explored for multiple anti-viral indications, including influenza, RSV, EB viral-related diseases